ClinicalTrials.gg
Not yet recruitingNCT07558200Updated Apr 30, 2026

Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of Intervention1:FXB0871 and Intervention2:FXB0871 in Solid Tumors, Non-Small Cell Lung Cancer and Hepatocellular Carcinoma, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma — 11 open to participants now, 15 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fosun Pharma.

Planned enrollment
10th of 17
138 · median 150
Started
2026
with 4 others
Phase 1
4 of 17
2 open now
Primary completion
2030-04
later than 13 of 14 live
Registered
16th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, this one is the 10th largest by planned enrollment, is one of 5 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 13 of the 14 other live ones, and was the 16th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma are open now, in 2 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, or all of them as a file.
02

Study summary

This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with selected locally advanced or metastatic solid tumors. In Part Ia, participants with selected solid tumors that have progressed after, are intolerant to, or are not suitable for standard therapy will receive FXB0871 in dose-escalation cohorts to determine the maximum tolerated dose and/or recommended phase 2 dose. In Part Ib, participants with PD-(L)1-resistant non-small cell lung cancer or hepatocellular carcinoma will receive FXB0871 in dose-expansion cohorts to further evaluate antitumor activity, safety, and dose optimization.

Read the detailed description

This first-in-human study consists of a dose-escalation part (Part Ia) and a dose-expansion part (Part Ib). In Part Ia, adults with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determinde dose cohorts using a Bayesian optimal interval design. The planned dosing schedule is every 2 weeks, with a dose-limiting toxicity observation period of the first 2 treatment cycles. Additional intermediate dose levels, cohort expansion, and schedule optimization to every 3 or 4 weeks may be allowed according to protocol-defined safety, PK/PD, and preliminary antitumor activity data.

Part Ib will start after determination of the monotherapy recommended phase 2 dose (RP2D). Cohort A will enroll participants with PD-(L)1-resistant locally advanced or metastatic non-small cell lung cancer and randomize them 1:1 to receive FXB0871 at the RP2D or at a lower dose selected on the basis of Part Ia data. Cohort B will enroll participants with PD-(L)1-resistant locally advanced or metastatic hepatocellular carcinoma to receive FXB0871 at the RP2D. Participants may continue study treatment for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

03

Conditions studied

  • Solid Tumors
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma

Keywords

  • FXB0871
  • TEV-56278
  • PD-1
  • IL-2
  • Dose Escalation
  • Dose Expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Signed .
  • Age ≥18 years.
  • confirmed selected locally advanced or solid tumor with progression on, intolerance to, or no suitable standard therapy.
  • performance status 0 or 1.
  • At least one per v1.1.
  • Pretreatment tumor tissue available (archival or fresh ).
  • ≥12 weeks.
  • Oxygen saturation ≥92% on room air.
  • >50%.
  • Adequate hematologic, coagulation, renal, hepatic, and cardiac function.
  • Women of and sexually active men must use highly effective .
  • Tumor-specific eligibility applies, including prior anti-PD-(L)1 treatment failure for the selected cohorts.

Key Exclusion Criteria:

  • Systemic anti-cancer therapy, major surgery, or radical radiotherapy within 4 weeks before first dose.
  • Prior treatment with IL-2, IL-15, or IL-7.
  • Active disease requiring systemic treatment or immunodeficiency.
  • Systemic (≥10 mg/day prednisone equivalent) or other therapy within 28 days before first dose, with limited protocol-defined exceptions.
  • Active or untreated central nervous system metastases, carcinomatous meningitis, or .
  • Uncontrolled infection or unresolved toxicities from prior therapy.
  • Clinically significant cardiovascular/cerebrovascular disease, uncontrolled effusions/ascites, uncontrolled hypertension, or >470 ms.
  • Active /C, syphilis, or infection.
  • Clinically significant interstitial lung disease or active noninfectious pneumonitis.
  • Pregnancy or breastfeeding.
  • Any other serious medical or psychiatric condition that, in the investigator's judgment, would make participation inappropriate.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Arm1:Part Ia Dose Escalation

    Participants with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determined dose-escalation cohorts or at intermediate dose levels every 2 weeks

    Biological: Intervention1:FXB0871

  • Experimental
    Arm2:Part Ib Dose Expansion (NSCLC, RP2D)

    Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks

    Biological: Intervention2:FXB0871

  • Experimental
    Arm3:Part Ib Dose Expansion(NSCLC, <RP2D)

    Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at a selected lower dose than RP2D from Phase Ia by intravenous infusion every 2 weeks

    Biological: Intervention3:FXB0871

  • Experimental
    Arm4:Part Ib Dose Expansion(HCC, RP2D)

    Participants with locally advanced or metastatic IO-resistant HCC will receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks

    Biological: Intervention4:FXB0871

Interventions

  • BiologicalIntervention1:FXB0871

    FXB0871 is administered by intravenous infusion at pre-determined dose level in Part Ia every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

    Also known as: TEV-56278

  • BiologicalIntervention2:FXB0871

    FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

    Also known as: TEV-56278

  • BiologicalIntervention3:FXB0871

    FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

    Also known as: TEV-56278

  • BiologicalIntervention4:FXB0871

    FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

    Also known as: TEV-56278

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose-limiting toxicities (DLTs) in Phase Ia

    Percentage of participants with protocol-defined DLTs during the DLT observation period in the dose-escalation phase

    Time frame: First 2 cycles after first dose (each cycle = 14 days; approximately 28 days).

  2. Incidence and severity of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia

    Safety assessed by the incidence of treatment-emergent adverse events, serious adverse events, AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia.

    Time frame: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first

  3. Objective response rate (ORR) in Phase Ib

    ORR defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 in Phase Ib.

    Time frame: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).

Secondary outcomes

  1. Objective response rate (ORR) in Phase Ia

    Objective response rate (ORR), defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed per RECIST v1.1 in Phase Ia.

    Time frame: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).

  2. Disease control rate (DCR) in Phase Ia

    Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed per RECIST v1.1 in Phase Ia.

    Time frame: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).

  3. Duration of response (DOR) in Phase Ia

    Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.

    Time frame: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).

  4. Progression-free survival (PFS) in Phase Ia

    Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.

    Time frame: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).

  5. Peak serum concentration (Cmax)

    Maximum observed concentration

    Time frame: Predose up to Day 8

  6. Time to maximum observed concentration (Tmax)

    Time to maximum observed drug concentration

    Time frame: Predose up to Day 8

  7. Area under the serum concentration-time curve (AUC0-last)

    Area under the serum concentration-time curve from time 0 to last measurable drug concentration

    Time frame: Predose up to Day 8

  8. Area under the serum concentration-time curve (AUC0-∞)

    Area under the concentration-time curve from time zero (pre-dose) extrapolation to infinite time

    Time frame: Predose up to Day 8

  9. Area under the serum concentration-time curve (AUCtau)

    Area under the concentration-time curve over the dosing interval

    Time frame: Predose up to Day 8

  10. Trough concentration (Ctrough)

    Observed concentration at the end of a dosing interval, immediately before next administration

    Time frame: up to Day 8

  11. Clearance (CL)

    Systemic (total body) clearance following iv administration

    Time frame: Predose up to Day 8

  12. Volume of distribution (Vz)

    Volume of distribution following iv administration

    Time frame: Predose up to Day 8

  13. Half-life (t1/2)

    Terminal phase half-life

    Time frame: Predose up to Day 8

  14. Average concentration (Cavg)

    Average concentration over a dosing interval

    Time frame: Predose up to Day 8

  15. Accumulation ratio (Rac)

    Accumulation ratio

    Time frame: Predose up to Day 8

  16. Incidence and severity of AEs/SAEs and AEs leading to dose modification or discontinuation in Phase Ib

    Safety and tolerability in the dose-expansion phase.

    Time frame: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first.

  17. ORR by modified RECIST (mRECIST) in the HCC cohort of Phase Ib

    ORR in participants with hepatocellular carcinoma assessed by mRECIST.

    Time frame: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).

  18. Disease control rate (DCR) in Phase Ib

    Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or SD, as assessed per RECIST v1.1 in Phase Ib.

    Time frame: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).

  19. Time to response (TTR) in Phase Ib

    Time to response (TTR), defined as the time from first dose to the first documented CR or PR, as assessed per RECIST v1.1 in Phase Ib.

    Time frame: From first dose to first documented CR or PR (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).

  20. Duration of response (DOR) in Phase Ib

    Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.

    Time frame: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).

  21. Title:Progression-free survival (PFS) in Phase Ib

    Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.

    Time frame: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).

  22. Overall survival (OS) in Phase Ib

    Overall survival measured from first dose to death from any cause.

    Time frame: From first dose until death from any cause (approximately up to 24 months).

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Apr 2030, 47 months later.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 47 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 30, 2026
StartEst.
May 15, 2026
Primary completionEst.
Apr 23, 2030
CompletionEst.
Nov 18, 2030
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07558200
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Apr 23, 2030 (estimated)
Completion
Nov 18, 2030 (estimated)
Last update
Apr 30, 2026

Study contacts

Caicun Zhou
Contact
caicunzhoudr@163.com
+86 13301825532
Fei Zhou
Contact
story185@126.com
+86 13801751704

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion